long term safety of glp-1 drugs have taken the world by storm, helping many people lose 11%–16% their body weight. But a new Cochrane review reveals something surprising: the evidence supporting these blockbuster injections isn't glp-1 long-term use safety Considering

Simulations predicted that for a compound with a human PCSK9 affinity below 1 nM, a once-weekly 50 mg dose would achieve robust free PCSK9 suppression (Supplementary Fig

Metabolic Resistance Point GLP-1 therapy is most strategically introduced when patients exhibit metabolic adaptations that counteract behavioral interventions: Plateau Effect: GLP-1 should be considered when patients adhering to a caloric deficit and exercise program experience a weight plateau, indicating a reduction in Total Daily Energy Expenditure (TDEE) as a physiological defense

Starting July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) is launching the Medicare GLP-1 Bridge, a short-term program that gives eligible Medicare Part D beneficiaries access to certain GLP-1 weight loss medications for a $50 copay per month

William Conway focuses on building long-term physician-patient relationships by practicing one-on-one patient care

KI is a senior clinical academic in liaison psychiatry specialising in diabetes and obesity